Cargando…
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
BACKGROUND: Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect. OBJECTIVE: To evaluate routinely collected data on nausea and vomiting among individuals on lir...
Autores principales: | Lean, M E J, Carraro, R, Finer, N, Hartvig, H, Lindegaard, M L, Rössner, S, Van Gaal, L, Astrup, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010971/ https://www.ncbi.nlm.nih.gov/pubmed/23942319 http://dx.doi.org/10.1038/ijo.2013.149 |
Ejemplares similares
-
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012) -
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012) -
Nausea, Vomiting, and Noninflammatory Diarrhea
por: Bobak, David A., et al.
Publicado: (2015) -
Postoperative nausea and vomiting
por: Moon, Young Eun
Publicado: (2014) -
COVID‐19, nausea, and vomiting
por: Andrews, Paul L R, et al.
Publicado: (2020)